Related Experiment Video
Updated: Apr 27, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Hypocholesterolemia is a consequence, not a cause, of kidney cancer: A bidirectional Mendelian randomization study
Xiaofei Zhang1, Zhao Tu2, Meishan Zhao2
1Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing, China; Institute of Urology, Beijing Municipal Health Commission, Beijing, China; Department of Urology, Xi'an Central Hospital, Xi'an Jiaotong University, Xi'an, China.
Background:
Kidney cancer patients often exhibit reduced circulating cholesterol, yet whether dyslipidemia is a cause or consequence of the disease remains unclear due to inherent limitations of observational studies. We integrated population-based data from NHANES with bidirectional Mendelian randomization (MR) to investigate the causal direction between lipid profiles and kidney cancer.
Methods:
Observational data were derived from National Health and Nutrition Examination Survey (NHANES) 2001-2018, comprising 102 self-reported kidney cancer cases and 45,366 cancer-free controls. All analyses accounted for the complex sampling design using survey weights, stratification, and primary sampling units. Bidirectional two-sample MR was conducted using genetic instruments for four lipid traits (low-density lipoprotein [LDL], high-density lipoprotein [HDL], triglycerides, total cholesterol [TC]) from IEU OpenGWAS and clear cell renal cell carcinoma (ccRCC) data from the largest available genome-wide association study (Purdue et al., n = 752,817), with no sample overlap. The primary analysis used inverse-variance weighted (IVW) estimation, complemented by sensitivity analyses including weighted median, MR-Egger, MR-PRESSO, and MR-RAPS.
Results:
Weighted linear regression (adjusted for age, sex, BMI, statin use, smoking, hypertension, diabetes) showed kidney cancer associated with lower LDL (β = -21.08 mg/dL, Bonferroni-corrected P = 0.0016); TC, HDL, and TG showed no significant associations. Forward MR found no causal effect of any lipid trait on ccRCC risk. Reverse MR demonstrated genetic predisposition to ccRCC associated with lower LDL (β = -0.020, P = 0.011), HDL (β = -0.016, P = 0.022), and TC (β = -0.009, P = 0.037), with robust results across sensitivity analyses.
Conclusions:
These findings suggest genetic liability to ccRCC is associated with lower circulating cholesterol, not dyslipidemia predisposing to kidney cancer, providing insight into the directionality question and implications for etiologic understanding and clinical surveillance without overstating causality.
Related Concept Videos
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Cholesterol: Significance and Regulation
Considering cholesterol and...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance